Literature DB >> 30444351

Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth.

Guanjun Deng1,2, Zhihong Sun1, Sanpeng Li1,2, Xinghua Peng1,2, Wenjun Li1, Lihua Zhou1, Yifan Ma1, Ping Gong1, Lintao Cai1.   

Abstract

Developing effective immunotherapies with low toxicity and high tumor specificity is the ultimate goal in the battle against cancer. Here, we reported a cell-membrane immunotherapy strategy that was able to eliminate primary tumors and inhibited distant tumors by using natural killer (NK) cell membrane cloaked photosensitizer 4,4',4'',4'''-(porphine-5,10,15,20-tetrayl) tetrakis (benzoic acid) (TCPP)-loaded nanoparticles (NK-NPs). The proteomic profiling of NK cell membranes was performed through shotgun proteomics, and we found that NK cell membranes enabled the NK-NPs to target tumors and could induce or enhance pro-inflammatory M1-macrophages polarization to produce antitumor immunity. The TCPP loaded in NK-NPs could induce cancer cell death through photodynamic therapy and consequently enhanced the antitumor immunity efficiency of the NK cell membranes. The results confirmed that NK-NPs selectively accumulated in the tumor and were able to eliminate primary tumor growth and produce an abscopal effect to inhibit distant tumors. This cell-membrane immunotherapeutic approach offers a strategy for tumor immunotherapy.

Entities:  

Keywords:  M1 macrophages; NK cell membranes; antitumor immunity; cell-membrane immunotherapy; photodynamic therapy

Mesh:

Substances:

Year:  2018        PMID: 30444351     DOI: 10.1021/acsnano.8b05292

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  49 in total

1.  Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds.

Authors:  Flavia Fontana; Raquél Bartolo; Hélder A Santos
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Biomimetic Nanotechnology toward Personalized Vaccines.

Authors:  Jiarong Zhou; Ashley V Kroll; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Adv Mater       Date:  2019-06-17       Impact factor: 30.849

Review 3.  Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.

Authors:  Xingzhou Peng; Junjie Wang; Feifan Zhou; Qian Liu; Zhihong Zhang
Journal:  Cell Mol Life Sci       Date:  2021-05-08       Impact factor: 9.261

Review 4.  Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.

Authors:  Hui Xu; Shuang Li; You-Shuo Liu
Journal:  Signal Transduct Target Ther       Date:  2022-07-11

Review 5.  Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy.

Authors:  Xiaoqiu Xu; Tong Li; Ke Jin
Journal:  Pharmaceutics       Date:  2022-05-23       Impact factor: 6.525

Review 6.  Multifunctional Nanosystems Powered Photodynamic Immunotherapy.

Authors:  Yunong Ma; Fengfeng Xiao; Cuixia Lu; Liewei Wen
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

Review 7.  Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.

Authors:  Bin Ji; Minjie Wei; Bin Yang
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

8.  What's Next after Lipid Nanoparticles? A Perspective on Enablers of Nucleic Acid Therapeutics.

Authors:  Ritam Das; Pintu Kanjilal; Jewel Medeiros; S Thayumanavan
Journal:  Bioconjug Chem       Date:  2022-04-04       Impact factor: 6.069

Review 9.  Chemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools.

Authors:  Leila Pourtalebi Jahromi; Mohammad-Ali Shahbazi; Aziz Maleki; Amir Azadi; Hélder A Santos
Journal:  Adv Sci (Weinh)       Date:  2021-03-01       Impact factor: 16.806

Review 10.  Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell.

Authors:  Chaopin Yang; Yue Li; Yaozhang Yang; Zhiyi Chen
Journal:  J Immunol Res       Date:  2020-01-21       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.